Siklos (hydroxyurea; Medunik) is now available in 1000mg triple-scored tablets to reduce the frequency of painful crises and need for blood transfusions in patients aged ≥2 years with sickle cell anemia with recurrent moderate to severe painful crises.
In addition to the 1000mg tablet, Siklos is also available in 100mg tablets. “Given that the new triple-scored Siklos 1000mg tablets can be divided into 4 equal parts of 250mg each, when combined with the 100mg tablets, it is now possible to adjust dosing in increments as small as 50mg (starting at a 200mg dose),” said Dany Hallé, Vice President, Commercial Affairs, at Medunik. The 100mg tablets, however, should not be split into smaller parts.
For patients who are unable to swallow the tablets, Siklos can be dispersed immediately before use in a small quantity of water in a teaspoon. As Siklos is a cytotoxic drug, caregivers are advised to wear disposable gloves when handling tablets or bottles containing the drug.
For more information visit siklosusa.com.
This article originally appeared on MPR